In the first quarter of 2020 Medivir entered into a licensing agreement with the US-based biotech company Tango Therapeutics for USP-1, one of Medivir’s preclinical research programs. Tango has announced that it expects to open an IND for TNG348, a USP1-inhibitor from the preclinical research program, in 2023. In September 2023 Tango Therapeutics received FDA clearance to start the TNG348, phase 1/2 clinical study. In January 2024 the first patient was dosed with TNG348. Through the agreement, Medivir is entitled to multiple development and commercial milestone payments as well as royalties on future sales. Dosing the first patient in a clinical trial triggers a milestone payment.